Added to YB: 2026-10-09
Pitch date: 2026-10-04
MIST [bullish]
Milestone Pharmaceuticals Inc.
-3.05%
current return
Author Info
No bio for this author
Company Info
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada.
Market Cap
$107.7M
Pitch Price
$0.82
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.02
P/E
-1.07
EV/Sales
33.68
Sector
Pharmaceuticals
Category
growth
M&A Hunter Portfolio Update: Tier 3 Core Convictions (Under $10) - Milestone Pharmaceuticals Inc.
MIST (hold): Milestone’s investment case now rests on launch execution: FDA-approved Cardamyst, an etripamil nasal spray for converting acute symptomatic PSVT episodes to sinus rhythm in adults, launched in the U.S. in February 2026 and had coverage for more than half of commercially insured lives by the Q2 update. Additional upside depends on ReVeRA-301 supporting a potential single-study supplemental NDA in AFib with rapid ventricular response.
Read full article (1 min)